
    
      Neonates diagnosed moderate/severe Hypoxic-Ischemic Encephalopathy after birth will receive
      routine therapy and be randomized to four arms for allogenic neural progenitor cells
      transplantation，paracrine factors of human mesenchymal stem cells intrathecal
      injection，combination of cell and factor or only routine therapy. Patients will be followed
      for neurodevelopmental outcome at 12 and 18 months in Pediatrics of Navy General Hospital.
      Magnetic Resonance Imaging, electroencephalogram, Bailey scores, Peabody development measure
      scale and Gross motor function measure assessment will be obtained in the following
      research.Results will be analyzed and described in study reports.
    
  